Macrogenics

This early-phase study tests an experimental drug called MGC026 in 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug by I…

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colorectal cancer) that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or stop…

This early-phase study tests a new drug called MGD024 in about 130 adults with certain blood cancers (like leukemia or lymphoma) that have not improved with standard treatments or have returned. The main goal is to find the safest dose and understand side effects. Participants re…

This study tests a new drug called lorigerlimab in about 80 people with advanced ovarian or other gynecologic cancers that no longer respond to standard chemotherapy. Participants receive the drug through an IV every 3 weeks. The goal is to see if the drug can shrink tumors and t…